In accord with the accumulating evidence indicating that the expression of PGC1-α in skeletal muscle declines with age and various metabolic diseases [31], we speculate that the effects of UC-MSCs on PGC-1α activity are likely to be of great significance in our experimental setting. Here, PPARGC1A is linked to metabolic disease.